Affitech A/S
http://www.affitech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Affitech A/S
Can BIOSECURE Maintain Its Virality In The TikTok Era?
With the sheen of inevitability now scuffed off the BIOSECURE Act, diplomatic efforts to reduce US dependence on Chinese APIs are increasing in prominence. And the power of the legislation itself could be determined by litigation about a video app.
Risks For Pharma Industry Remain As BIO Shifts Course On BIOSECURE Act
Trade group’s break from WuXi Apptec allows BIO to reset its lobbying approach under its new CEO but doesn’t negate the business and supply chain disruptions that biopharma would feel from the proposed legislation.
US Senate Advances BIOSECURE Legislation As China Biotech Security Heats Up
The US Senate moves closer to new legislation that would restrict Chinese "biotech companies of concern” from operating in the US, potentially causing broad and far-reaching impact.
US Draft Bill Highlights Perceived China Biotech Threat
A draft bill from the US House related to national security issues sent WuXi Biologics' shares tumbling over concerns around increased US scrutiny of Chinese firms, which a company clarification did little to dispel.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Actigen Limited
- Epimmune
- Pharmexa
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice